UK-based specials manufacturer Quantum Pharmaceutical has appointed Andrew Matthews as operations director to maintain high performance standards and develop the business.
Matthews has more than 12 years’ experience in the pharmaceutical and healthcare industries. He has specialist knowledge in product areas for sterile and non-sterile medicines.
Matthews’ experience in quality driven operations management for unlicensed and licensed medicines will assist Quantum Pharmaceutical in its aim of strengthening links with hospitals, care home and home care pharmaceutical providers, as the company broadens its core customer base.
‘Andrew had an excellent CV and great track record as head of manufacturing ‘Specials’ with his former employer, domiciliary care organisation Healthcare At Home,’ said Andy Scaife, md of Quantum Pharmaceutical.
‘With knowledge of this niche sector of the pharmaceutical industry, Andrew is an excellent fit for Quantum but, most importantly, he brings a new skills set which will be of great benefit as we look to exploit new market opportunities.
Quantum Pharmaceutical appoints operations director
Andrew Matthews brings a new set of skills to the company
You may also like
Manufacturing
Patented device reinvents Solid Phase Extraction
Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
Manufacturing
Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility
The €29m ATLab site will target up to 10,000 doses annually and its two-hour proximity to major European airports meets the critical 24-hour production-to-administration window imposed by lead-212's 10.6-hour half-life
Manufacturing
Catalent launches ten-month gene-to-drug substance programme for complex biologics
The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting master cell bank release by month seven and bulk drug substance lot release by month ten
Design & Build
Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite
The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale